Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 14/20 | 0.80 |
| ▸ | MMEL1 | Q495T6 | 4/20 | 0.80 |
| ▸ | ACE | P12821 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3710898 | 1.00 | MME (0.80) | MMEMMEL1ACE | |
| Sacubitril SCHEMBL8214132 | 0.90 | MME (0.77) | MMEMMEL1ACE | |
| Sacubitril SCHEMBL22420467 | 0.90 | MME (0.77) | MMEMMEL1ACE | |
| Sacubitril SCHEMBL489040 | 0.90 | MME (0.77) | MMEMMEL1ACE | |
| Sacubitril SCHEMBL1908525 | 0.90 | MME (0.77) | MMEMMEL1ACE | |
| Sacubitril SCHEMBL18059568 | 0.90 | MME (0.77) | MMEMMEL1ACE | |
| Sacubitril SCHEMBL2707112 | 0.90 | MME (0.77) | MMEMMEL1ACE | |
| Sacubitril SCHEMBL18574632 | 0.90 | MME (0.77) | MMEMMEL1ACE | |
| Sacubitril SCHEMBL18059569 | 0.90 | MME (0.77) | MMEMMEL1ACE | |
| SCHEMBL3709244 | 0.89 | MME (1.00) | MMEMMEL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673974-B2 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | claimed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8673974-B2 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065956-A1 | SUBSTITUTED AMINO BISPHENYL PENTANOIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065956-A1 | SUBSTITUTED AMINO BISPHENYL PENTANOIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122977-A1 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122977-A1 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122977-A1 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122977-A1 | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors | REN, MME, AGTR1 | MME 2/4885MMEL1 545/4885ACE 6/4885 |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885MMEL1 118/4885ACE 92/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885MMEL1 118/4885ACE 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.